天中依脉品牌怎么样 申请店铺

我要投票 天中依脉在医疗保健行业中的票数:1129 更新时间:2026-01-24
公司简介: 天中依脉集团成立于2009年,现拥有三家全资子公司:天津市天中依脉科技开发有限公司、依脉人工智能医疗科技(天津)有限公司和汇汉依脉智能科技(上海)有限公司。公司坐落于天津滨海高新区华苑产业

外推网助力天中依脉品牌出海!将品牌入驻外推网,定制天中依脉品牌推广信息,可以显著提高天中依脉产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

天中依脉怎么样

公司简介:

天中依脉集团成立于2009年,现拥有三家全资子公司:天津市天中依脉科技开发有限公司、依脉人工智能医疗科技(天津)有限公司和汇汉依脉智能科技(上海)有限公司。公司坐落于天津滨海高新区华苑产业区,是我国专注于中医四诊客观化技术研究和中医诊疗设备的研发与制造的科技型国内知名高新企业之一。公司具有国内一流的中医诊疗仪器研发团队,完善的生产体系和检验设备,产品质量稳定可靠。公司的脉象仪,舌象仪等产品获得国家中医药管理局中医诊疗设备2011版第一批推荐品目。

天中依脉是较早专注于中医诊疗客观化的高新技术企业,核心技术脱胎于天津中医药大学、天津大学历届专家及从上世纪80年代开始的“中医客观化技术”研究。依脉人工智能医疗科技(天津)有限公司是天中依脉的全资子公司,致力于发展“中医云脑”智能化云中医服务,参与国家“一带一路”中医文化传播与技术推广,全面支持国家医联体建设、家庭医生签约服务等领域的中医药服务,践行健康中国战略。

 15625675637646365997938.png

2009年创立至今,天中依脉与国内三十余家高校及高级医疗机构建立了长期深入的科研合作关系,拥有200多项国家专利及软件著作等知识产权,产品服务于500余家医疗机构,成为中医智能行业的领航者。

公司荣誉:

●2009年,参与国家中医诊断仪器国际以及国家行业标准制定

●2009年,参与火星MARS500计划项目

●2011年,参与承担国家973项目

●2011年,舌象仪和脉象仪同时入选国家中医药管理局《中医诊疗设备推荐品目2011版第一批》

●2012年,参与国家自然基金项目

●2012年,参与国家十二五支撑项目

●2013年,获得中国科技部“科技型中小企业技术创新基金”

●2018年,天中依脉“智云中医”中医医联体管理、服务体系上市,并与全国多家中医机构建立合作关系。

公司愿景:

1、中医客观化诊疗技术,中医健康大数据和人工智能科技的国际领导品牌!

2、建立开放、共享、共赢的中医健康数据服务平台,打造中医健康产业生态群。

3、推动先进的中医科技和传统文化走向世界,服务全人类健康!

公司使命:

创新中医科技,传承中医文化,引领健康生活!

Company profile: Tianzhong Yimai group, founded in 2009, now has three wholly-owned subsidiaries: Tianjin Tianzhong Yimai Technology Development Co., Ltd., Yimai artificial intelligence medical technology (Tianjin) Co., Ltd. and Huihan Yimai Intelligent Technology (Shanghai) Co., Ltd. The company is located in Huayuan Industrial Zone, Binhai high tech Zone, Tianjin. It is one of the well-known high-tech enterprises in China, which focuses on the research and development and manufacturing of the four diagnosis and treatment objectification technology of traditional Chinese medicine and the diagnosis and treatment equipment of traditional Chinese medicine. The company has a domestic first-class R & D team of TCM diagnosis and treatment instruments, perfect production system and testing equipment, and stable and reliable product quality. The company's pulse instrument, tongue instrument and other products have won the first batch of recommended items of Chinese medicine diagnosis and treatment equipment 2011 edition of the State Administration of traditional Chinese medicine. Tianzhong Yimai is an early high-tech enterprise focusing on the objectification of TCM diagnosis and treatment. Its core technology was born from the experts of Tianjin University of traditional Chinese medicine, Tianjin University and the research on "objectification technology of TCM" since the 1980s. One belt, one road, China's Tianjin medical company (China) is a wholly-owned subsidiary of the Chinese medicine company. It is committed to the development of the "Yun Nao" intelligent Chinese medicine service, participating in the "one belt and one way" Chinese medicine culture dissemination and technology promotion, and fully supporting the traditional Chinese medicine service in the fields of national medical conjoined construction, family doctor's contract service and so on, and practicing the healthy China strategy. Since its establishment in 2009, Tianzhong Yimai has established a long-term and in-depth scientific research cooperation relationship with more than 30 universities and advanced medical institutions in China. It has more than 200 national patents and software works and other intellectual property rights. Its products serve more than 500 medical institutions and become a leader in the intelligent industry of traditional Chinese medicine. Honors of the company: ● in 2009, participated in the development of international and national industry standards for diagnostic instruments of traditional Chinese medicine ● in 2009, participated in Mars Mars 500 program project ● in 2011, participated in the national 973 project ● in 2011, tongue imager and pulse imager were selected into the first batch of recommended items of Chinese medical diagnosis and treatment equipment 2011 edition by the State Administration of traditional Chinese medicine ● in 2012, participated in the national natural fund project ● 201 2 years, participated in the national 12th Five Year Plan support project ● in 2013, won the "technology innovation fund for small and medium-sized enterprises of science and technology type" of the Ministry of science and technology of China ● in 2018, Tianzhong Yimai "Zhiyun TCM" TCM management and service system went public, and established cooperation with many TCM institutions across the country. Company vision: 1. Objective diagnosis and treatment technology of traditional Chinese medicine, international leading brand of health big data and artificial intelligence technology of traditional Chinese medicine! 2. Establish an open, shared and win-win TCM health data service platform, and build an ecosystem of TCM health industry. 3. Promote the advanced technology of traditional Chinese medicine and traditional culture to the world, and serve the health of all mankind! Mission of the company: innovate TCM technology, inherit TCM culture and lead healthy life!

本文链接: https://brand.waitui.com/93449407c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前涨跌不一,Arm涨超2%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,Arm涨超2%,英伟达涨超1%,谷歌涨0.1%,微软涨0.06%;特斯拉跌0.17%,奈飞跌0.11%,亚马逊跌0.07%,苹果跌0.03%。

13分钟前

热门中概股美股盘前涨跌互现,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前涨跌互现,截至发稿,阿里巴巴、京东跌超1%,小鹏汽车跌近1%,网易跌0.48%,蔚来跌0.21%;百度涨超1%,拼多多涨0.75%,理想汽车涨0.42%,B站涨0.09%。

13分钟前

晶升股份:拟购买为准智能100%股份,交易作价8.57亿元

36氪获悉,晶升股份公告,公司拟通过发行股份及支付现金的方式购买本尚科技等10名交易对方持有的为准智能100%股份,同时募集配套资金。为准智能100%股份的交易作价为8.57亿元。本次交易构成关联交易和重大资产重组,但不构成重组上市。交易完成后,为准智能将成为上市公司控股子公司。

13分钟前

天合光能:将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”

36氪获悉,天合光能公告,公司拟缩减“年产35GW直拉单晶项目”的募集资金投资金额,不再实施二期15GW项目,并将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”。新项目预计2026年底建成并投入运营。公司表示,本次变更有利于提高募集资金使用效率,合理优化资源配置,巩固市场地位,不会对公司正常经营产生不利影响。该事项尚需提交公司股东会和债券持有人会议审议通过后方可实施。

13分钟前

宝洁第二财季净销售额222亿美元,同比增长1%

当地时间1月22日,宝洁公司发布2026财年第二季度(2025年10-12月)财报。财报显示,第二财季净销售额为222亿美元,同比增长1%;摊薄后每股净收益为1.78美元,同比下降5%。该公司维持2026财年总销售额同比增长1%至5%的指引区间,将2026财年摊薄后每股净收益增长指引从原先的3%-9%调整至1%-6%。(界面)

13分钟前

本页详细列出关于天中依脉的品牌信息,含品牌所属公司介绍,天中依脉所处行业的品牌地位及优势。
咨询